These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 28947039

  • 1. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.
    Crim C, Calverley PMA, Anderson JA, Holmes AP, Kilbride S, Martinez FJ, Brook RD, Newby DE, Yates JC, Celli BR, Vestbo J, SUMMIT investigators.
    Respir Med; 2017 Oct; 131():27-34. PubMed ID: 28947039
    [Abstract] [Full Text] [Related]

  • 2. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C.
    Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
    [Abstract] [Full Text] [Related]

  • 3. A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD.
    Rodrigo GJ, Neffen H.
    Pulm Pharmacol Ther; 2017 Feb; 42():1-6. PubMed ID: 27864038
    [Abstract] [Full Text] [Related]

  • 4. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
    Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE, SUMMIT Investigators.
    Lancet; 2016 Apr 30; 387(10030):1817-26. PubMed ID: 27203508
    [Abstract] [Full Text] [Related]

  • 5. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD.
    Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM.
    Ann Am Thorac Soc; 2015 Jan 30; 12(1):27-34. PubMed ID: 25490706
    [Abstract] [Full Text] [Related]

  • 6. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C.
    Respir Med; 2013 Apr 30; 107(4):560-9. PubMed ID: 23352226
    [Abstract] [Full Text] [Related]

  • 7. Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction.
    Martinez FJ, Vestbo J, Anderson JA, Brook RD, Celli BR, Cowans NJ, Crim C, Dransfield M, Kilbride S, Yates J, Newby DE, Niewoehner D, Calverley PM, SUMMIT Investigators.
    Am J Respir Crit Care Med; 2017 Apr 01; 195(7):881-888. PubMed ID: 27767328
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A.
    Respir Med; 2015 Sep 01; 109(9):1155-63. PubMed ID: 26117292
    [Abstract] [Full Text] [Related]

  • 9. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
    Bhatt SP, Dransfield MT, Cockcroft JR, Wang-Jairaj J, Midwinter DA, Rubin DB, Scott-Wilson CA, Crim C.
    Int J Chron Obstruct Pulmon Dis; 2017 Sep 01; 12():351-365. PubMed ID: 28176907
    [Abstract] [Full Text] [Related]

  • 10. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
    Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID.
    Lancet Respir Med; 2015 Jun 01; 3(6):435-42. PubMed ID: 25878028
    [Abstract] [Full Text] [Related]

  • 11. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug 01; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 12. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM.
    Lancet Respir Med; 2013 May 01; 1(3):210-23. PubMed ID: 24429127
    [Abstract] [Full Text] [Related]

  • 13. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, Calverley PM.
    Respir Med; 2013 Apr 01; 107(4):550-9. PubMed ID: 23332861
    [Abstract] [Full Text] [Related]

  • 14. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
    Bollmeier SG, Prosser TR.
    Ann Pharmacother; 2014 Feb 01; 48(2):250-7. PubMed ID: 24259654
    [Abstract] [Full Text] [Related]

  • 15. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
    Lee L, Kerwin E, Collison K, Nelsen L, Wu W, Yang S, Pascoe S.
    Respir Med; 2017 Oct 01; 131():148-157. PubMed ID: 28947022
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk.
    Brook RD, Anderson JA, Calverley PM, Celli BR, Crim C, Denvir MA, Magder S, Martinez FJ, Rajagopalan S, Vestbo J, Yates J, Newby DE, SUMMIT Investigators.
    Heart; 2017 Oct 01; 103(19):1536-1542. PubMed ID: 28416587
    [Abstract] [Full Text] [Related]

  • 17. Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk.
    Calverley PMA, Anderson JA, Brook RD, Crim C, Gallot N, Kilbride S, Martinez FJ, Yates J, Newby DE, Vestbo J, Wise R, Celli BR, SUMMIT (Study to Understand Mortality and Morbidity) Investigators.
    Am J Respir Crit Care Med; 2018 Jan 01; 197(1):47-55. PubMed ID: 28737971
    [Abstract] [Full Text] [Related]

  • 18. 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study.
    Lipson DA, Birk R, Brealey N, Zhu CQ.
    Adv Ther; 2020 Dec 01; 37(12):4894-4909. PubMed ID: 33011864
    [Abstract] [Full Text] [Related]

  • 19. The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial).
    Zheng J, Zhong N, Wang C, Huang Y, Chen P, Wang L, Hui F, Zhao L, Wang H, Luo L, Du X, Han Goh A, Lipson DA.
    COPD; 2018 Dec 01; 15(4):334-340. PubMed ID: 30265816
    [Abstract] [Full Text] [Related]

  • 20. Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups.
    Bakerly ND, Woodcock A, Collier S, Leather DA, New JP, Crawford J, Harvey C, Vestbo J, Boucot I.
    Respir Med; 2019 Feb 01; 147():58-65. PubMed ID: 30704700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.